Name | Number of supported studies | Average coverage | |
|---|---|---|---|
| mast cell | 14 studies | 37% ± 21% | |
| endothelial cell | 13 studies | 23% ± 9% | |
| fibroblast | 10 studies | 23% ± 7% | |
| macrophage | 7 studies | 20% ± 3% | |
| endothelial cell of vascular tree | 7 studies | 19% ± 4% | |
| glutamatergic neuron | 7 studies | 37% ± 25% | |
| pericyte | 6 studies | 23% ± 5% | |
| erythroblast | 5 studies | 45% ± 8% | |
| myofibroblast cell | 5 studies | 25% ± 8% | |
| smooth muscle cell | 5 studies | 20% ± 3% | |
| oligodendrocyte precursor cell | 5 studies | 24% ± 6% | |
| connective tissue cell | 4 studies | 27% ± 4% | |
| astrocyte | 4 studies | 23% ± 6% | |
| interneuron | 4 studies | 38% ± 22% | |
| retinal bipolar neuron | 3 studies | 38% ± 16% | |
| capillary endothelial cell | 3 studies | 20% ± 2% | |
| endothelial cell of lymphatic vessel | 3 studies | 18% ± 4% | |
| amacrine cell | 3 studies | 55% ± 10% | |
| vein endothelial cell | 3 studies | 17% ± 1% | |
| GABAergic neuron | 3 studies | 50% ± 3% | |
| erythrocyte | 3 studies | 35% ± 13% | |
| neuron | 3 studies | 39% ± 15% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
|---|---|---|---|---|---|---|
| brain | 100% | 4901.24 | 2639 / 2642 | 100% | 79.71 | 702 / 705 |
| breast | 100% | 2348.40 | 457 / 459 | 83% | 8.25 | 929 / 1118 |
| prostate | 99% | 1705.45 | 242 / 245 | 77% | 7.12 | 385 / 502 |
| skin | 85% | 1472.67 | 1532 / 1809 | 85% | 17.92 | 403 / 472 |
| lung | 100% | 1967.70 | 576 / 578 | 66% | 5.51 | 757 / 1155 |
| thymus | 97% | 1059.30 | 633 / 653 | 68% | 6.60 | 409 / 605 |
| adrenal gland | 76% | 568.02 | 195 / 258 | 83% | 25.58 | 192 / 230 |
| ovary | 100% | 3367.40 | 180 / 180 | 45% | 3.91 | 193 / 430 |
| bladder | 100% | 2305.10 | 21 / 21 | 41% | 4.08 | 208 / 504 |
| kidney | 76% | 687.17 | 68 / 89 | 64% | 9.80 | 577 / 901 |
| uterus | 99% | 2980.37 | 169 / 170 | 40% | 7.38 | 182 / 459 |
| intestine | 96% | 1563.99 | 928 / 966 | 39% | 3.33 | 208 / 527 |
| esophagus | 80% | 1389.09 | 1157 / 1445 | 45% | 3.26 | 82 / 183 |
| stomach | 67% | 921.38 | 241 / 359 | 55% | 4.98 | 156 / 286 |
| adipose | 100% | 3068.28 | 1204 / 1204 | 0% | 0 | 0 / 0 |
| blood vessel | 100% | 2404.50 | 1334 / 1335 | 0% | 0 | 0 / 0 |
| spleen | 98% | 1111.90 | 235 / 241 | 0% | 0 | 0 / 0 |
| pancreas | 6% | 36.98 | 20 / 328 | 90% | 11.83 | 160 / 178 |
| eye | 0% | 0 | 0 / 0 | 91% | 13.13 | 73 / 80 |
| heart | 89% | 968.06 | 765 / 861 | 0% | 0 | 0 / 0 |
| lymph node | 0% | 0 | 0 / 0 | 76% | 4.57 | 22 / 29 |
| muscle | 32% | 225.26 | 260 / 803 | 0% | 0 | 0 / 0 |
| tonsil | 0% | 0 | 0 / 0 | 29% | 1.75 | 13 / 45 |
| liver | 4% | 24.73 | 9 / 226 | 18% | 1.35 | 75 / 406 |
| peripheral blood | 0% | 1.81 | 3 / 929 | 0% | 0 | 0 / 0 |
| abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
| ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
| GO_2000272 | Biological process | negative regulation of signaling receptor activity |
| GO_0005886 | Cellular component | plasma membrane |
| GO_0005737 | Cellular component | cytoplasm |
| GO_0031718 | Molecular function | type 1 cannabinoid receptor binding |
| GO_0005515 | Molecular function | protein binding |
| Gene name | CNRIP1 |
| Protein name | CB1 cannabinoid receptor-interacting protein 1 CB1 cannabinoid receptor-interacting protein 1 (CRIP-1) |
| Synonyms | C2orf32 |
| Description | FUNCTION: [Isoform 1]: Suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. .; FUNCTION: [Isoform 2]: Does not suppress cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. . FUNCTION: Suppresses cannabinoid receptor CNR1-mediated tonic inhibition of voltage-gated calcium channels. . |
| Accessions | ENST00000409862.1 ENST00000409559.7 [Q96F85-2] B8ZZB8 ENST00000263655.4 [Q96F85-1] Q96F85 |